Search
Bucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Tofisopam
go.drugbank.com/drugs/DB08811InvestigationalTofisopam (marketed under brand names Emandaxin and Grandaxin) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. … The D-enantiomer ([dextofisopam]) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome.
Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP3A InhibitorsThymol
go.drugbank.com/drugs/DB02513ApprovedInvestigationalA phenol obtained from thyme oil or other volatile oils. It is used as a stabilizer in pharmaceutic preparations. … It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)
Mixtures: VICKS VAPORUB BUHARLASAN MERHEM, 1 ADETSynonyms: 5-Methyl-2-(1-Methylethyl)Phenol, 2-isopropyl-5-methylphenolMebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnMebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.
Octamoxin
go.drugbank.com/drugs/DB09249ApprovedWithdrawnOctamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.
Synonyms: 2-octylhydrazineGrowth hormone-releasing peptide 1
go.drugbank.com/drugs/DB19259InvestigationalGrowth hormone-releasing peptide 1 is under investigation in clinical trial NCT00381602 (A Phase II, Randomized, Cross-over, Vehicle-controlled, Double-blind, Multicenter Study of the Safety, Pharmacodynamics … , and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis).
Synonyms: L-alanyl-l-histidyl-3-(2-naphthalenyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide, Ala-his-3-(2-naphthalenyl)-d-ala-ala-trp-d-phe-lys-nh2Lifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalIt is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. … Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsCurcuma aromatica root oil
go.drugbank.com/drugs/DB11301ApprovedThe wild ginger has been used as a cosmetic herbal where its rhizomes exhibit a distinct fragrance and color. … Curcuma aromatica root oil is also suggested to have antibacterial activity.
ChulaCov19 mRNA vaccine
go.drugbank.com/drugs/DB16445ExperimentalThe next phase of this study is for phase I and II clinical trials (NCT04566276) beginning in January 2021. … The ChulaCov19 vaccine is mRNA-based and was developed in Thailand’s Chulalongkorn University in collaboration with the University of Pennsylvania in the US[L30673, L30678].
Isradipine
go.drugbank.com/drugs/DB00270ApprovedIt is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. … It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: OPTASIL ®, CALBLOCK® TABLETAS